Ankap Partners
SelectiveNew York, NYHealthcare, Biotechnology, Healthcare ServicesLast fund filed 1998
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| AnKap Partners | 1998 | Indefinite | $21M | 51 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Robert Anderson | Selective | None listed | 31 | 2 |
| Barbara Burke DiCostanzo | Quiet | None listed | 0 | 0 |
| Ralph Kaplan | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Ankap Partners’s own portfolio companies, based on 28 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Ankap Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
No other firm shares a filed board seat with Ankap Partners yet. That is a gap in what we have read, not a claim that Ankap Partners invests alone.
A shared board seat: a company where filings name a Ankap Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.